There are currently 841 clinical trials in Jacksonville, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Florida, Mayo Clinic - Jacksonville, Mayo Clinic and Mayo Clinic Florida. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Breaking Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes
NCT05849753
Recruiting
50 children/adolescents (ages 6 to <18yrs) with T1D in suboptimal control (HbA1c≥8.0%) and lower SES (below 200% poverty line) on insulin therapy (either injections or open-loop pumps) will be recruited at Nemours ~ 1/3 each AA, Hispanic/Latino, non-Hispanic whites. All families that qualify and agree to transition to closed-loop technologies will be recruited to allow data to be gathered before and after use of devices. They will go through the process of approval with the assistance of an insu... Read More
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
07/26/2023
Locations: Nemours Children's Health, Jacksonville, Florida
Conditions: Diabetes Mellitus, Type 1, Child, Delivery of Health Care, Equipment and Supplies
Register for Updates
Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma
NCT04674683
Recruiting
This is a phase 3 study to compare the efficacy and safety of HBI-8000 or Placebo combined with nivolumab on patients with unresectable or metastatic melanoma and eligible patients who are not adolescents or patients with new, progressive brain metastasis will be stratified by PD-L1 expression and LDH level.
Gender:
All
Ages:
12 years and above
Trial Updated:
07/25/2023
Locations: Baptist MD Anderson Cancer Center, Jacksonville, Florida
Conditions: Unresectable or Metastatic Melanoma, Progressive Brain Metastasis
Register for Updates
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI
NCT05681702
Recruiting
Two strategies have both proven to be effective in reducing bleeding complications while preserving efficacy compared with maintaining long-term DAPT with aspirin and a potent P2Y12 inhibitor: a) DAPT de-escalation (i.e., switching from prasugrel or ticagrelor to clopidogrel while maintaining aspirin) and b) potent P2Y12 inhibitor monotherapy (i.e., maintaining prasugrel or ticagrelor and dropping aspirin). These strategies have been tested in a number of trials and have led to changes in practi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/24/2023
Locations: University of Florida, Jacksonville, Florida
Conditions: Coronary Artery Disease
Register for Updates
Trial of Parkinson's And Zoledronic Acid
NCT03924414
Recruiting
This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the Nationa... Read More
Gender:
All
Ages:
60 years and above
Trial Updated:
07/24/2023
Locations: Mayo Clinic, Jacksonville, Florida
Conditions: Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia With Lewy Bodies
Register for Updates
Pivotal-Safety and Therapeutic Measures of tDCS in Patients With Refractory Focal Epilepsy
NCT04770337
Recruiting
This is a multiple site, randomized, double blinded parallel-group controlled study. The purpose of this study is to evaluate efficacy, safety, and tolerability of repeated, daily sessions with the STARSTIM device, which delivers transcranial cathodal direct current stimulation (tDCS). Subjects will be treated with STARTSTIM or sham device for 10 sessions over a 2-week period. The subjects will be followed for an additional 10 weeks post treatment. Quality of Life questionnaires and adverse even... Read More
Gender:
All
Ages:
9 years and above
Trial Updated:
07/21/2023
Locations: University of Florida Jacksonville, Jacksonville, Florida
Conditions: Refractory Epilepsy, Focal Seizure, Seizures, Focal, Seizures, Epilepsy in Children, Epilepsy, Epilepsy, Tonic-Clonic
Register for Updates
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
NCT03554083
Recruiting
This early phase I pilot trial studies how well vemurafenib, cobimetinib, and atezolizumab work in treating patients with high-risk stage III melanoma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as atezolizumab and tiragolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving vemurafenib, cobime... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/20/2023
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Register for Updates
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
NCT05732103
Recruiting
The goal of this phase 1/2 multicenter, open-label, singe arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS). The phase 1 part of the study consists of sequential standard 3 + 3 dose escalation, where patients will receive ascending doses of CTX-712 to determine the recommended phase 2 dose (... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Register for Updates
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
NCT04372615
Recruiting
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Autoimmune Encephalitis, Encephalitis
Register for Updates
Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients
NCT05375994
Recruiting
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/19/2023
Locations: Mayo Clinic Cancer Center, Jacksonville, Florida
Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease
Register for Updates
Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing
NCT04404894
Recruiting
This registry will evaluate treatment selection for patients with newly diagnosed, localized prostate cancer following Prolaris testing. It will measure the proportion of men who initially select treatment with active surveillance, the time frame between active surveillance selection and any change in treatment, and clinical outcomes.
Gender:
Male
Ages:
18 years and above
Trial Updated:
07/18/2023
Locations: University of Florida - Jacksonville, Jacksonville, Florida
Conditions: Prostate Cancer
Register for Updates
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma in Patients Undergoing Craniotomy
NCT05789394
Recruiting
This phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblastoma that has come back (recurrent) who are undergoing brain surgery (craniotomy). Glioblastoma is the most common and most aggressive form of primary and malignant tumor of the brain. Currently, the standard of care for this disease includes surgical resection, followed by radiation with chemotherapy and tumor treating fields. Despite thi... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
07/14/2023
Locations: Mayo Clinic in Florida, Jacksonville, Florida
Conditions: Recurrent Glioblastoma
Register for Updates
Golf, Physical Rehabilitation, and Movement Disorders
NCT05651776
Recruiting
The importance of physical activity for individuals with movement disorders, including Parkinson disease and Essential tremor, has been established. Barriers including patient engagement continue to limit effectiveness. Golf requires skills found challenging to individuals with movement disorders. This study seeks to assess the feasibility and effectiveness of an outpatient-based rehabilitation program incorporating golf skills and activities on functional measures and quality of life.
Gender:
All
Ages:
Between 18 years and 105 years
Trial Updated:
07/11/2023
Locations: University of Florida, Jacksonville, Florida
Conditions: Parkinson Disease, Movement Disorders
Register for Updates